Vojo Vukovic Biography and Net Worth

Chief Medical Officer of Delcath Systems

Dr. Vukovic is an experienced drug development executive with a distinguished career in cancer research and global clinical development. His experience spans early- to late-stage clinical development projects across multiple anticancer modalities and tumor types and global medical affairs programs supporting several commercial oncology drugs. He has held the position of Senior Vice President and Chief Medical Officer at Aileron Therapeutics, Taiho Oncology Inc, and Synta Pharmaceuticals Inc, overseeing various facets of clinical development, medical affairs, and corporate strategy.

Dr. Vukovic earned his MD from the University of Sarajevo in Bosnia and Herzegovina and an MSc in radiation biology and a PhD in tumor biology from the University of Toronto in Canada. His work has been published in several high-impact scientific journals, and he is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Society of Hematology, and the European Society for Medical Oncology.

What is Vojo Vukovic's net worth?: The estimated net worth of Vojo Vukovic is at least $601.20 thousand as of November 16th, 2023. Dr. Vukovic owns 60,000 shares of Delcath Systems stock worth more than $601,200 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Vukovic may own. Learn More about Vojo Vukovic's net worth.
How do I contact Vojo Vukovic?: The corporate mailing address for Dr. Vukovic and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected]. Learn More on Vojo Vukovic's contact information.
Has Vojo Vukovic been buying or selling shares of Delcath Systems?: Vojo Vukovic has not been actively trading shares of Delcath Systems in the last ninety days. Most recently, on Thursday, November 16th, Vojo Vukovic bought 60,000 shares of Delcath Systems stock. The stock was acquired at an average cost of $2.48 per share, with a total value of $148,800.00. Following the completion of the transaction, the insider now directly owns 60,000 shares of the company's stock, valued at $148,800. Learn More on Vojo Vukovic's trading history.
Who are Delcath Systems' active insiders?: Delcath Systems' insider roster includes Gil Aharon (Director), Gerard Michel (CEO), Sandra Pennell (SVP), John Purpura (COO), Steven Salamon (Director), John Sylvester (Director), and Vojo Vukovic (Chief Medical Officer). Learn More on Delcath Systems' active insiders.
Are insiders buying or selling shares of Delcath Systems?: During the last twelve months, Delcath Systems insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $98,095.00. The most recent insider tranaction occured on November, 11th when CEO Gerard J Michel bought 11,500 shares worth more than $98,095.00. Insiders at Delcath Systems own 17.4% of the company. Learn More about insider trades at Delcath Systems.
Information on this page was last updated on 11/11/2025.

Vojo Vukovic Insider Trading History at Delcath Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2023	Buy	60,000	$2.48	$148,800.00	60,000

Vojo Vukovic Buying and Selling Activity at Delcath Systems

Delcath Systems Company Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Today's Range

Now: $10.02

$9.57

$10.12

50 Day Range

MA: $9.94

$8.19

$12.36

2 Week Range

Now: $10.02

$8.12

$18.23

Volume

605,955 shs

Average Volume

796,411 shs

Market Capitalization

$353.81 million

P/E Ratio

1,002.00

Dividend Yield

N/A

Beta

0.41